Background: To evaluate the clinical effectiveness of a topical sialogogue spray (malic acid, 1%) in the treatment of xerostomia in patients with chronic Graft versus Host Disease (cGVHD). Material and Methods: This study was designed as a randomized double-blind clinical study. Twenty-eight patients with cGVHD suffering from xerostomia were divided into 2 groups: The first group (14 patients) received a topical sialagogue spray containing malic acid 1% (SalivAktive®) whereas the second group (14 patients) received a placebo. Both groups received treatment for 2 weeks. Dry Mouth Questionnaire (DMQ) scores and unstimulated salivary flows rate were collected before and after treatment. Results: DMQ scores increased significantly from 1.3 ± 0.4 to 3.5 ± 0.4 points (p<0.05) after two weeks of treatment with malic acid, whereas in the control group DMQ scores increased from 1.2 ± 0.7 points to 1.4 ± 0.6 (p>0.05). The unstimulated salivary flow rate in patients treated with malic acid increased significantly from 0.15 ± 0.06 mL/min to 0.24± 0.08 mL/min, while that of the patients treated with placebo went from 0.16 ± 0.07 mL/ min to 0.17 ± 0.09 mL/min (p>0.05). Conclusions: Malic acid 1% spray can be considered effective in the treatment of GVHD induced xerostomia.

Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease / Bardellini, E.; Amadori, F.; Conti, G.; Veneri, F.; Majorana, A.. - In: MEDICINA ORAL, PATOLOGÍA ORAL Y CIRUGÍA BUCAL. - ISSN 1698-6946. - 24:2(2019), pp. e190-e194. [10.4317/medoral.22699]

Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease

Veneri F.;
2019

Abstract

Background: To evaluate the clinical effectiveness of a topical sialogogue spray (malic acid, 1%) in the treatment of xerostomia in patients with chronic Graft versus Host Disease (cGVHD). Material and Methods: This study was designed as a randomized double-blind clinical study. Twenty-eight patients with cGVHD suffering from xerostomia were divided into 2 groups: The first group (14 patients) received a topical sialagogue spray containing malic acid 1% (SalivAktive®) whereas the second group (14 patients) received a placebo. Both groups received treatment for 2 weeks. Dry Mouth Questionnaire (DMQ) scores and unstimulated salivary flows rate were collected before and after treatment. Results: DMQ scores increased significantly from 1.3 ± 0.4 to 3.5 ± 0.4 points (p<0.05) after two weeks of treatment with malic acid, whereas in the control group DMQ scores increased from 1.2 ± 0.7 points to 1.4 ± 0.6 (p>0.05). The unstimulated salivary flow rate in patients treated with malic acid increased significantly from 0.15 ± 0.06 mL/min to 0.24± 0.08 mL/min, while that of the patients treated with placebo went from 0.16 ± 0.07 mL/ min to 0.17 ± 0.09 mL/min (p>0.05). Conclusions: Malic acid 1% spray can be considered effective in the treatment of GVHD induced xerostomia.
2019
24
2
e190
e194
Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease / Bardellini, E.; Amadori, F.; Conti, G.; Veneri, F.; Majorana, A.. - In: MEDICINA ORAL, PATOLOGÍA ORAL Y CIRUGÍA BUCAL. - ISSN 1698-6946. - 24:2(2019), pp. e190-e194. [10.4317/medoral.22699]
Bardellini, E.; Amadori, F.; Conti, G.; Veneri, F.; Majorana, A.
File in questo prodotto:
File Dimensione Formato  
22699.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 401.28 kB
Formato Adobe PDF
401.28 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1295555
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact